Bergenbio’s bemcentinib joins fast-tracked Accord program targeting COVID-19 April 29, 2020 By Nuala Moran No Comments LONDON – The U.K. has started a fast track national trial of experimental drugs in COVID-19 patients, with Bergenbio ASA’s phase II cancer immunotherapy, bemcentinib, the first of six products that are due to join the study.Read More